Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ajay K GopalGilles Salles

Abstract

Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee-assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle 3) and cytokines/chemokines (baseline/cycle 2) were performed for available samples. Results Between March 2013 and May 2016, 110 patients with a median of three prior lines of therapy were enrolled. At median follow-up of 27.7 months, ORR was 20.9% (95% CI, 13.7% to 29.7%, which did not meet the 18% lower-bound threshold for the primary end point). Twelve patients achieved a complete response (11%; 95% CI, 5.8% to 18.3%). Median duration of response was 19.4 months (range, 1 to ≥ 33 months), with a median progression-free survival of 4.6 mon...Continue Reading

References

Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J O Armitage, D D Weisenburger
Aug 19, 2000·Cancer Chemotherapy and Pharmacology·T NishimuraS Nishimura
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Nov 19, 2004·The New England Journal of Medicine·Sandeep S DaveLouis M Staudt
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jun 15, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jonathan M IrishRonald Levy
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
May 7, 2013·Haematologica·Emmanuel BachyUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Oct 2, 2014·The Journal of Clinical Investigation·Jason A DubovskyBruce R Blazar
Oct 10, 2015·Blood·Dennis E Discher, Paul A Ney
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Y CheahM L Wang
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DreylingUNKNOWN ESMO Guidelines Committee
Jan 27, 2017·Oncoimmunology·Carolina Cubillos-ZapataEduardo López-Collazo
Apr 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CasuloC R Flowers

❮ Previous
Next ❯

Citations

Jul 5, 2019·European Journal of Haematology·Reyad Dada
Sep 27, 2019·Blood·Krish PatelJohn M Pagel
Dec 10, 2019·American Journal of Hematology·Arnold Freedman, Eric Jacobsen
May 19, 2020·American Society of Clinical Oncology Educational Book·Jeremy S AbramsonSonali M Smith
Aug 3, 2020·Current Opinion in Oncology·Marie José KerstenCatherine Thieblemont
Jul 28, 2020·Expert Opinion on Drug Safety·Shinichi MakitaKensei Tobinai
Mar 31, 2019·Targeted Oncology·Fabienne Lucas, Jennifer A Woyach
May 18, 2019·American Society of Clinical Oncology Educational Book·Mark Roschewski, Brian T Hill
May 10, 2020·HemaSphere·Kai HübelAjay K Gopal
Jun 8, 2019·British Journal of Haematology·Carla Casulo
Dec 7, 2019·Hematology·Caron A Jacobson
Feb 6, 2019·Therapeutic Advances in Hematology·Grerk Sutamtewagul, Brian K Link
Nov 15, 2019·HemaSphere·Kai HübelMartin Dreyling
Mar 8, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ajay K GopalNancy L Bartlett
Dec 29, 2020·Clinical Lymphoma, Myeloma & Leukemia·Solomon A GrafAjay K Gopal
Feb 23, 2021·Drugs·Michael Northend, William Townsend
Mar 7, 2021·Journal of Personalized Medicine·Karthik Nath, Maher K Gandhi
Mar 24, 2021·Current Hematologic Malignancy Reports·Jennifer GirardTycel Phillips
Apr 3, 2021·Current Hematologic Malignancy Reports·Loretta J Nastoupil
Feb 14, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jumana Afaghani, Justin Taylor
May 22, 2021·Cancer Management and Research·Thomas A Ollila, Adam J Olszewski
Jul 2, 2021·Journal of Hematology & Oncology·Walter Hanel, Narendranath Epperla
Aug 7, 2021·Blood and Lymphatic Cancer : Targets and Therapy·Georgios Pongas, Bruce Cheson

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.